Combines leading in silico lead optimisation technology with the synthetic and natural compound libraries and network of scientists to create lead libraries
InterBioScreen (IBS), provider of unique chemical compound libraries, and Quantum Pharmaceuticals, high-tech drug discovery company, have announced a new project to create a revolutionary product for the drug discovery market.
The joint project, QuantumLead, combines the in silico lead optimisation technology of Quantum Pharmaceuticals with the unique synthetic and natural compound libraries and network of scientists of IBS to create Q-Lead-Libraries.
Q-Lead-Libraries are libraries of compounds, which are ranked according to their constant affinity to particular protein targets.
They are designed to allow biotech and pharmaceutical companies to achieve a dramatic acceleration of the drug discovery R and D process by reducing or eliminating the time involved in screening and optimisation of hits and leads.
Using Q-Lead-Libraries will enable biotech and pharmaceuticals companies to find exclusive novel drug candidates more quickly and at a lower cost.
The technology behind Q-Lead-Libraries is Quantum Pharmaceuticals's proprietary intermolecular modeling tools and accurate affinity calculations. The technology provides for full flexibility of both ligands and proteins and takes into account all factors of binding free energy including solvation effects, Van Der Waals energy in solution, as well as electrostatic and entropy contribution.
The joint in-house drug development program is expected to produce a broad range of novel drug candidates for HIV-1 integrase (Aids), HSP90 (oncology) and beta-secretase (Alzheimer's Disease) that will be marketed and out-licensed by both companies at the preclinical stage.
